Electrolyte Blood Press.  2015 Dec;13(2):41-45. 10.5049/EBP.2015.13.2.41.

Hypertension in Chronic Glomerulonephritis

• Ihm CG

• KMID: 2152085
• DOI: http://doi.org/10.5049/EBP.2015.13.2.41

Abstract

Chronic glomerulonephritis (GN), which includes focal segmental glomerulosclerosis and proliferative forms of GN such as IgA nephropathy, increases the risk of hypertension. Hypertension in chronic GN is primarily volume dependent, and this increase in blood volume is not related to the deterioration of renal function. Patients with chronic GN become salt sensitive as renal damage including arteriolosclerosis progresses and the consequent renal ischemia causes the stimulation of the intrarenal renin-angiotensin-aldosterone system(RAAS). Overactivity of the sympathetic nervous system also contributes to hypertension in chronic GN. According to the KDIGO guideline, the available evidence indicates that the target BP should be < or =140mmHg systolic and < or =90mmHg diastolic in chronic kidney disease patients without albuminuria. In most patients with an albumin excretion rate of > or =30mg/24 h (i.e., those with both micro-and macroalbuminuria), a lower target of < or =130mmHg systolic and < or =80mmHg diastolic is suggested. The use of agents that block the RAAS system is recommended or suggested in all patients with an albumin excretion rate of > or =30mg/ 24 h. The combination of a RAAS blockade with a calcium channel blocker and a diuretic may be effective in attaining the target BP, and in reducing the amount of urinary protein excretion in patients with chronic GN.

Keyword

Chronic glomerulonephritis; Volume dependent; RAAS blockade

MeSH Terms

Albuminuria
Arteriolosclerosis
Blood Volume
Calcium Channels
Glomerulonephritis*
Glomerulonephritis, IGA
Glomerulosclerosis, Focal Segmental
Humans
Hypertension*
Ischemia
Renal Insufficiency, Chronic
Sympathetic Nervous System
Calcium Channels

Reference

1. Nachman PH, Jennette JC, Falk RJ. Primary glomerular disease. In : Brenner BM, Rector FC, editors. The kidney. 10th ed. Philadelphia: Saunders;2011. p. 1101–1191.

2. Orofino L, Quereda C, Lamas S, Orte L, Gonzalo A, Mampaso F, et al. Hypertension in primary chronic glomerulonephritis: analysis of 288 biopsied patients. Nephron. 1987; 45:22–26. PMID: 3808144.

3. Csiky B, Kovács T, Wágner L, Vass T, Nagy J. Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant. 1999; 14:86–90. PMID: 10052483.

4. Kaplan NM. Renal parenchymal hypertension. Clinical Hypertension. 7th ed. Baltimore: Williams & Wilkins;1998. p. 281–299.

5. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004; 43:699–706. PMID: 14981063.

6. Valvo E, Gammaro L, Bedogna V, Giorgetti PG, Tonon M, Panzetta GO, et al. Hypertension in primary immunoglobulin A nephropathy (Berger’s disease): hemodynamic alterations and mechanisms. Nephron. 1987; 45:219–223. PMID: 3553975.

7. Ikee R, Kobayashi S, Saigusa T, Namikoshi T, Yamada M, Hemmi N, et al. Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res. 2006; 29:15–22. PMID: 16715649.

8. Bazzi C, Stivali G, Rachele G, Rizza V, Casellato D, Nangaku M. Arteriolar hyalinosis and arterial hypertension as possible surrogate markers of reduced interstitial blood flow and hypoxia in glomerulonephritis. Nephrology. 2015; 20:11–17. PMID: 25230383.

9. Konishi Y, Okada N, Okamura M, Morikawa T, Okumura M, Yoshioka K, et al. Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy. Hypertension. 2001; 38:81–85. PMID: 11463764.

10. Jang WS, Jeong KH, Moon JY, Lee SH, Cho JH, Lee TW, et al. Relationship between glomerulomegaly and clinicopathologic findings in IgA nephropathy. Clin Nephrol. 2012; 78:470–477. PMID: 22909783.

11. Kim YG, Song SB, Lee SH, Moon JY, Jeong KH, Lee TW, et al. Urinary angiotensinogen as a predictive marker in patients with immunoglobulin A nephropathy. Clin Exp Nephrol. 2011; 15:720–726. PMID: 21695414.

12. Lee HJ, Choi SY, Jeong KH, Sung JY, Moon SK, Moon JY, et al. Association of C1q deposition with renal outcomes in IgA nephropathy. Clin Nephrol. 2013; 80:98–104. PMID: 23587123.

13. Nishiyama A, Konishi Y, Ohashi N, Morikawa T, Urushihara M, Maeda I, et al. Urnary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant. 2011; 26:170–177. PMID: 20615910.

14. Kobori H, Katsurada A, Ozawa Y, Satou R, Miyata K, Hase N, et al. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun. 2007; 358:156–163. PMID: 17482564.

15. Konishi Y, Nishiyama A, Morikawa T, Kitabayashi C, Shibata M, Hamada M, et al. Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy. Hypertension. 2011; 58:205–211. PMID: 21670416.

16. Kim SM, Chin HJ, Oh YK, Kim YS, Kim S, Lim CS. Blood pressure-related genes and the progression of IgA nephropathy. Nephron Clin Pract. 2009; 113:c301–c308. PMID: 19729965.

17. Shinzawa M, Yamamoto R, Nagasawa Y, Shoji T, Obi Y, Namba T, et al. Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy. Clin Exp Nephrol. 2012; 16:250–258. PMID: 22072187.

18. Park M, Jeong K, Moon J, Lee T, Ihm C, Lee S. The Treatment Response to Angiotensin Receptor Blocker According to ACE Gene Polymorphism in Patients with IgA Nephropathy. Korean J Nephrol. 2008; 27:13–19.

19. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158:825–830. PMID: 23732715.

20. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507–520. PMID: 24352797.

21. ESH/ESC Task Force for the Management of Arterial Hypertension: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013; 31:1925–1938. PMID: 24107724.

22. ACCORD Study Group. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575–1585. PMID: 20228401.

23. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014; 371:2255–2266. PMID: 25399733.

24. SPRINT Research Group. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373:2103–2116. PMID: 26551272.

25. Nelson RG, Tuttle KR. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD. Blood Purif. 2007; 25:112–114. PMID: 17170547.

26. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet. 2008; 372:547–553. PMID: 18707986.

27. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes with different fixeddose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375:1173–1181. PMID: 20170948.